{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:40:35Z","timestamp":1789576835298,"version":"build-2803163510"},"reference-count":117,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":3520,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s13311-013-0222-5","type":"journal-article","created":{"date-parts":[[2013,10,10]],"date-time":"2013-10-10T01:17:08Z","timestamp":1381367828000},"page":"166-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder"],"prefix":"10.1016","volume":"11","author":[{"given":"Leslie J.","family":"Cloud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Zutshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart A.","family":"Factor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-013-0222-5_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-2007-971169","article-title":"Tardive dyskinesia","volume":"27","author":"Soares-Weiser","year":"2007","journal-title":"Semin Neurol"},{"key":"10.1007\/s13311-013-0222-5_bib2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/mds.20823","article-title":"Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?","volume":"21","author":"Tarsy","year":"2006","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0222-5_bib3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/15622970802481895","article-title":"Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug","volume":"10","author":"Li","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib4","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/1531-8257(199909)14:5<873::AID-MDS1027>3.0.CO;2-U","article-title":"Possible tardive dystonia resulting from clozapine therapy","volume":"14","author":"Molho","year":"1999","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0222-5_bib5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/ncpgasthep0442","article-title":"Drug Insight: from disturbed motility to disordered movement\u2013a review of the clinical benefits and medicolegal risks of metoclopramide","volume":"3","author":"Pasricha","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.1007\/s13311-013-0222-5_bib6","article-title":"An update on tardive dyskinesia: from phenomenology to treatment","volume":"3","author":"Waln","year":"2013","journal-title":"Tremor Other Hyperkinet Mov"},{"key":"10.1007\/s13311-013-0222-5_bib7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"8","author":"Bhidayasiri","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0222-5_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0447.1964.tb05731.x","article-title":"Neurological symptoms in pharmacotherapy of psychoses","volume":"40","author":"Faurbye","year":"1964","journal-title":"Acta Psychiatr Scand"},{"key":"10.1007\/s13311-013-0222-5_bib9","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/WNL.32.12.1335","article-title":"Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs","volume":"32","author":"Burke","year":"1982","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0222-5_bib10","series-title":"Hyperkinetic movement disorders: differential diagnosis and treatment","first-page":"331","article-title":"Tardive dyskinesias","author":"Revuelta","year":"2012"},{"key":"10.1007\/s13311-013-0222-5_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/mds.870020207","article-title":"Life-threatening tardive dyskinesia caused by metoclopramide","volume":"2","author":"Samie","year":"1987","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0222-5_bib12","series-title":"Drug induced movement disorders","first-page":"257","article-title":"Neuroleptic-Induced tardive dyskinesia variants","author":"Skidmore","year":"2005"},{"key":"10.1007\/s13311-013-0222-5_bib13","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1176\/ajp.149.9.1206","article-title":"Tardive dyskinesia in elderly psychiatric patients: a 5-year study","volume":"149","author":"Yassa","year":"1992","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib14","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/archpsyc.1995.03950210050010","article-title":"Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients","volume":"52","author":"Jeste","year":"1995","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib15","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/mds.22707","article-title":"Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis","volume":"24","author":"Tenback","year":"2009","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0222-5_bib16","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/01.jcp.0000144888.43449.54","article-title":"Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center","volume":"24","author":"Wonodi","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-013-0222-5_bib17","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1176\/ajp.150.6.966","article-title":"Diabetes and development of tardive dyskinesia","volume":"150","author":"Woerner","year":"1993","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/archpsyc.1991.01810270071010","article-title":"The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study","volume":"48","author":"Ganzini","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib19","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1176\/ajp.155.11.1521","article-title":"Prospective study of tardive dyskinesia in the elderly: rates and risk factors","volume":"155","author":"Woerner","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib20","first-page":"254","article-title":"Integrating incidence and prevalence of tardive dyskinesia","volume":"22","author":"Kane","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"10.1007\/s13311-013-0222-5_bib21","series-title":"Drug induced movement disorders","first-page":"213","article-title":"Tardive dyskinesia","author":"Hyde","year":"2005"},{"key":"10.1007\/s13311-013-0222-5_bib22","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1176\/ajp.152.12.1724","article-title":"Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients","volume":"152","author":"Chatterjee","year":"1995","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib23","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1600-0404.1977.tb01431.x","article-title":"Spontaneous buccolinguofacial dyskinesia in the elderly","volume":"56","author":"Delwaide","year":"1977","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-013-0222-5_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.1972.01750250081011","article-title":"Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine","volume":"27","author":"Kazamatsuri","year":"1972","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/archpsyc.1972.01750250086012","article-title":"Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate","volume":"27","author":"Kazamatsuri","year":"1972","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/YCO.0b013e328017f6b1","article-title":"Tardive dyskinesia: eliminated, forgotten, or overshadowed?","volume":"20","author":"Remington","year":"2007","journal-title":"Curr Opin Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib27","article-title":"Metoclopramide: drug use data review","author":"Kaplan","year":"2005","journal-title":"memorandum. Food and Drug Administration, Center for Drug Evaluation and Research"},{"key":"10.1007\/s13311-013-0222-5_bib28","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archpsyc.1982.04290040069010","article-title":"Tardive dyskinesia: prevalence and risk factors, 1959 to 1979","volume":"39","author":"Kane","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/schbul\/18.4.701","article-title":"Gender differences in tardive dyskinesia: a critical review of the literature","volume":"18","author":"Yassa","year":"1992","journal-title":"Schizophr Bull"},{"key":"10.1007\/s13311-013-0222-5_bib30","doi-asserted-by":"crossref","first-page":"52S","DOI":"10.1097\/00004714-198808001-00010","article-title":"Tardive dyskinesia: prevalence, incidence, and risk factors","volume":"8","author":"Kane","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-013-0222-5_bib31","first-page":"133","article-title":"Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications","volume":"54","author":"Glazer","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/archpsyc.1996.01830040049009","article-title":"Incidence and correlates of tardive dyskinesia in first episode of schizophrenia","volume":"53","author":"Chakos","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib33","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mds.870120403","article-title":"The emerging role of clozapine in the treatment of movement disorders","volume":"12","author":"Factor","year":"1997","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0222-5_bib34","article-title":"A call for caution in the use of antipsychotic drugs","author":"Friedman","year":"2012","journal-title":"New York Times,"},{"key":"10.1007\/s13311-013-0222-5_bib35","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/archgenpsychiatry.2012.647","article-title":"National trends in the office-based treatment of children, adolescents, and adults with antipsychotics","volume":"69","author":"Olfson","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Curr Opin Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib37","doi-asserted-by":"crossref","first-page":"e25588","DOI":"10.1371\/journal.pone.0025588","article-title":"Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder","volume":"6","author":"Bakker","year":"2011","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0222-5_bib38","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1192\/bjp.bp.108.050088","article-title":"Extrapyramidal side-effects of antipsychotics in a randomised trial","volume":"193","author":"Miller","year":"2008","journal-title":"Br J Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib39","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib41","first-page":"327","article-title":"Does clozapine cause tardive dyskinesia?","volume":"54","author":"Kane","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib42","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/pds.1122","article-title":"Patterns of prescription of four major antipsychotics: a retrospective study based on medical records of psychiatric inpatients","volume":"14","author":"Gasquet","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1007\/s13311-013-0222-5_bib43","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1192\/bjp.154.4.523","article-title":"The course of tardive dyskinesia in patients on long-term neuroleptics","volume":"154","author":"Bergen","year":"1989","journal-title":"Br J Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib44","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/978-3-642-70140-5_11","article-title":"Tardive dyskinesia: reversible and irreversible","volume":"2","author":"Casey","year":"1985","journal-title":"Psychopharmacology Suppl"},{"key":"10.1007\/s13311-013-0222-5_bib45","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.56.6.805","article-title":"The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up","volume":"56","author":"Fernandez","year":"2001","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0222-5_bib46","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1192\/bjp.157.4.585","article-title":"Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication","volume":"157","author":"Glazer","year":"1990","journal-title":"Br J Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00002826-198406000-00006","article-title":"The reversibility of \u201cpermanent\u201d tardive dyskinesia","volume":"7","author":"Klawans","year":"1984","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0222-5_bib48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.schres.2007.10.018","article-title":"Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment","volume":"100","author":"Modestin","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1007\/s13311-013-0222-5_bib49","unstructured":"Zutshi D, Cloud L, Factor S. Reversibility of tardive syndromes. 64th Annual Meeting of the American Academy of Neurology, 2012, New Orleans, LA. Abstract."},{"key":"10.1007\/s13311-013-0222-5_bib50","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/archpsyc.1980.01780250054006","article-title":"Changes in prevalence, severity, and recovery in tardive dyskinesia with age","volume":"37","author":"Smith","year":"1980","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib51","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1192\/bjp.158.6.822","article-title":"The prediction of chronic persistent versus intermittent tardive dyskinesia. A retrospective follow-up study","volume":"158","author":"Glazer","year":"1991","journal-title":"Br J Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib52","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1600-0447.1992.tb03264.x","article-title":"A 10-year follow-up study of tardive dyskinesia","volume":"86","author":"Yassa","year":"1992","journal-title":"Acta Psychiatr Scand"},{"key":"10.1007\/s13311-013-0222-5_bib53","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/0006-3223(92)90071-7","article-title":"Predictors of the course of tardive dyskinesia in patients receiving neuroleptics","volume":"32","author":"Bergen","year":"1992","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00002826-198205010-00002","article-title":"Tardive dyskinesia: pharmacology and clinical implications","volume":"5","author":"Goetz","year":"1982","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0222-5_bib55","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/archpsyc.1983.01790220020003","article-title":"Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures","volume":"41","author":"Gardos","year":"1984","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004714-198105000-00005","article-title":"Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics","volume":"1","author":"Shenoy","year":"1981","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-013-0222-5_bib57","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0140-6736(80)90107-5","article-title":"Covert dyskinesia in ambulatory schizophrenia","volume":"2","author":"Carpenter","year":"1980","journal-title":"Lancet"},{"key":"10.1007\/s13311-013-0222-5_bib58","first-page":"118","article-title":"Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia [proceedings]","volume":"17","author":"Branchey","year":"1981","journal-title":"Psychopharmacol Bull"},{"key":"10.1007\/s13311-013-0222-5_bib59","first-page":"4","article-title":"Molindone and haloperidol in tardive dyskinesia","volume":"46","author":"Glazer","year":"1985","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib60","doi-asserted-by":"crossref","first-page":"36S","DOI":"10.1097\/00004714-199502001-00007","article-title":"Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study","volume":"15","author":"Chouinard","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-013-0222-5_bib61","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.4088\/JCP.v64n1110","article-title":"Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study","volume":"64","author":"Bai","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib62","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4088\/JCP.09m05155yel","article-title":"A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia","volume":"71","author":"Chan","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib63","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2710.2011.01290.x","article-title":"Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature","volume":"37","author":"Ono","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"10.1007\/s13311-013-0222-5_bib64","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.158.4.503","article-title":"The effects of clozapine on tardive dyskinesia","volume":"158","author":"Lieberman","year":"1991","journal-title":"Br J Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib65","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11940-011-0117-x","article-title":"Tardive dyskinesia","volume":"13","author":"Aia","year":"2011","journal-title":"Curr Treat Options Neurol"},{"key":"10.1007\/s13311-013-0222-5_bib66","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"Huntington Study Group","year":"2006","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0222-5_bib67","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1176\/ajp.156.8.1279","article-title":"Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol","volume":"156","author":"Ondo","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib68","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.21222","article-title":"Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders","volume":"22","author":"Kenney","year":"2007","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0222-5_bib69","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","article-title":"Long-term effects of tetrabenazine in hyperkinetic movement disorders","volume":"48","author":"Jankovic","year":"1997","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0222-5_bib70","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1345\/aph.1P312","article-title":"Tetrabenazine for the treatment of tardive dyskinesia","volume":"45","author":"Leung","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1007\/s13311-013-0222-5_bib71","first-page":"41","article-title":"Evaluation of reserpine and alpha-methyldopa in the treatment of tardive dyskinesia","volume":"16","author":"Huang","year":"1980","journal-title":"Psychopharmacol Bull"},{"key":"10.1007\/s13311-013-0222-5_bib72","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF00426466","article-title":"Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia","volume":"73","author":"Huang","year":"1981","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1007\/s13311-013-0222-5_bib73","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/14737175.6.1.7","article-title":"Tetrabenazine in the treatment of hyperkinetic movement disorders","volume":"6","author":"Kenney","year":"2006","journal-title":"Expert Rev Neurother"},{"key":"10.1007\/s13311-013-0222-5_bib74","first-page":"719","article-title":"Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration","volume":"17","author":"Allen","year":"1982","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib75","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM197103252841216","article-title":"Amantadine for dyskinesia tarda","volume":"284","author":"Vale","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-013-0222-5_bib76","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1056\/NEJM197110072851516","article-title":"Amantadine hydrochloride treatment of tardive dyskinesia","volume":"285","author":"Decker","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-013-0222-5_bib77","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0222-5_bib78","first-page":"141","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson's disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib79","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00002826-200003000-00004","article-title":"The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study","volume":"23","author":"Snow","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0222-5_bib80","first-page":"21","article-title":"Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties","volume":"320","author":"Jackisch","year":"1992","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1007\/s13311-013-0222-5_bib81","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00004714-199704000-00004","article-title":"A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia","volume":"17","author":"Angus","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-013-0222-5_bib82","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/WNF.0b013e3181ffde32","article-title":"Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"33","author":"Pappa","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0222-5_bib83","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4088\/JCP.v69n0405","article-title":"Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"69","author":"Woods","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib84","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/01.WNL.0000073538.60021.50","article-title":"Levetiracetam as a treatment for tardive dyskinesia: a case report","volume":"61","author":"McGavin","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0222-5_bib85","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/01.jcp.0000203823.60603.80","article-title":"Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series","volume":"26","author":"Bona","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-013-0222-5_bib86","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/mds.20835","article-title":"Levetiracetam in tardive dyskinesia: an open label study","volume":"21","author":"Konitsiotis","year":"2006","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0222-5_bib87","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.WNF.0000228807.49044.7D","article-title":"Levetiracetam in tardive dyskinesia","volume":"29","author":"Meco","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0222-5_bib88","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00702-010-0472-x","article-title":"Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial","volume":"117","author":"Wolz","year":"2010","journal-title":"J Neural Transm"},{"key":"10.1007\/s13311-013-0222-5_bib89","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000468574","article-title":"Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs","volume":"17","author":"Kabes","year":"1982","journal-title":"Int Pharmacopsychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib90","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4088\/JCP.v68n0709","article-title":"Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study","volume":"68","author":"Libov","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib91","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/ajp.147.4.445","article-title":"Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy","volume":"147","author":"Thaker","year":"1990","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib92","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/mds.25231","article-title":"Propranolol therapy for tardive dyskinesia revisited","volume":"27","author":"Factor","year":"2012","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0222-5_bib93","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/ajp.137.4.495","article-title":"Low-dose propranolol in tardive dyskinesia","volume":"137","author":"Bacher","year":"1980","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib94","first-page":"391","article-title":"Propranolol in the treatment of tardive-dyskinesia","volume":"18","author":"Perenyi","year":"1983","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib95","first-page":"328","article-title":"Treatment of tardive-dyskinesia with propranolol","volume":"43","author":"Schrodt","year":"1982","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib96","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1176\/ajp.143.10.1290","article-title":"Elevation of thioridazine plasma levels by propranolol","volume":"143","author":"Silver","year":"1986","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib97","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt197925119","article-title":"Inhibition of propranolol metabolism by chlorpromazine","volume":"25","author":"Vestal","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"10.1007\/s13311-013-0222-5_bib98","first-page":"241","article-title":"Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study","volume":"22","author":"Lerner","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0222-5_bib99","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.4088\/JCP.v68n1103","article-title":"Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study","volume":"68","author":"Lerner","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib100","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4088\/JCP.09m05125yel","article-title":"Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"72","author":"Zhang","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib101","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s002130050959","article-title":"Branched chain amino acids decrease tardive dyskinesia symptoms","volume":"143","author":"Richardson","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1007\/s13311-013-0222-5_bib102","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4088\/JCP.v65n0116","article-title":"Branched chain amino acid treatment of tardive dyskinesia in children and adolescents","volume":"65","author":"Richardson","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib103","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1176\/appi.ajp.160.6.1117","article-title":"Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men","volume":"160","author":"Richardson","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib104","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.parkreldis.2010.04.007","article-title":"Lingual protrusion dystonia: frequency etiology and botulinum toxin therapy","volume":"16","author":"Esper","year":"2010","journal-title":"Park Rel Disord"},{"key":"10.1007\/s13311-013-0222-5_bib105","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WNF.0b013e31818ddbc4","article-title":"Botulinum toxin in painful tardive dyskinesia","volume":"32","author":"Tschopp","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0222-5_bib106","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.pnpbp.2007.09.010","article-title":"Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature","volume":"32","author":"Hennings","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib107","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.pnpbp.2007.10.004","article-title":"Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study","volume":"32","author":"Slotema","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib108","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1600-0404.2008.01115.x","article-title":"A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation","volume":"119","author":"Kefalopoulou","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-013-0222-5_bib109","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/archpsyc.64.2.170","article-title":"Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia","volume":"64","author":"Damier","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib110","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/mds.10705","article-title":"Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia","volume":"19","author":"Schrader","year":"2004","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0222-5_bib111","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/00029330-200605010-00017","article-title":"Deep brain stimulation in the treatment of tardive dystonia","volume":"119","author":"Zhang","year":"2006","journal-title":"Chin Med J (Engl)"},{"key":"10.1007\/s13311-013-0222-5_bib112","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00005053-198506000-00005","article-title":"Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale","volume":"173","author":"Lane","year":"1985","journal-title":"J Nerv Ment Dis"},{"key":"10.1007\/s13311-013-0222-5_bib113","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0447.1993.tb03366.x","article-title":"The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity","volume":"87","author":"Gerlach","year":"1993","journal-title":"Acta Psychiatr Scand"},{"key":"10.1007\/s13311-013-0222-5_bib114","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.870010305","article-title":"Natural history and treatment of tardive dystonia","volume":"1","author":"Kang","year":"1986","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0222-5_bib115","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.biopsych.2012.04.032","article-title":"Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba","volume":"72","author":"Zhang","year":"2012","journal-title":"Biol Psychiatry"},{"issue":"Suppl.)","key":"10.1007\/s13311-013-0222-5_bib116","first-page":"5","article-title":"Tardive dyskinesia: pathophysiology and animal models","volume":"61","author":"Casey","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-013-0222-5_bib117","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/070674370505000907","article-title":"Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction","volume":"50","author":"Margolese","year":"2005","journal-title":"Can J Psychiatry"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0222-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-013-0222-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923016471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923016471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0222-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:10:29Z","timestamp":1761808229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923016471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":117,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1878747923016471"],"URL":"https:\/\/doi.org\/10.1007\/s13311-013-0222-5","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-013-0222-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}